Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

Revenue, Net

Revenue, Net %Chg

Revenue, Net Common Size

Cost of Revenues

Cost of Revenues %Chg

Cost of Revenues Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

Acquired in-Process Research and Development

Acquired in-Process Research and Development %Chg

Acquired in-Process Research and Development Common Size

General and Administrative

General and Administrative %Chg

General and Administrative Common Size

Total Operating Expenses

Total Operating Expenses %Chg

Total Operating Expenses Common Size

Loss from Operations

Loss from Operations %Chg

Loss from Operations Common Size

Change in Fair Value of Investments

Change in Fair Value of Investments %Chg

Change in Fair Value of Investments Common Size

Gain on Sale of Investment

Gain on Sale of Investment %Chg

Gain on Sale of Investment Common Size

Change in Fair Value of Debt and Liability Instruments

Change in Fair Value of Debt and Liability Instruments %Chg

Change in Fair Value of Debt and Liability Instruments Common Size

Gain on Termination of Sumitomo Options

Gain on Termination of Sumitomo Options %Chg

Gain on Termination of Sumitomo Options Common Size

Gain on Deconsolidation of Subsidiaries

Gain on Deconsolidation of Subsidiaries %Chg

Gain on Deconsolidation of Subsidiaries Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Other Income, Net

Other Income, Net %Chg

Other Income, Net Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Loss Before Income Taxes

Loss Before Income Taxes %Chg

Loss Before Income Taxes Common Size

Loss from Continuing Operations Before Income Taxes

Loss from Continuing Operations Before Income Taxes %Chg

Loss from Continuing Operations Before Income Taxes Common Size

Income Tax Expense

Income Tax Expense %Chg

Income Tax Expense Common Size

Loss from Continuing Operations, Net of Tax

Loss from Continuing Operations, Net of Tax %Chg

Loss from Continuing Operations, Net of Tax Common Size

Loss from Discontinued Operations, Net of Tax

Loss from Discontinued Operations, Net of Tax %Chg

Loss from Discontinued Operations, Net of Tax Common Size

Net Loss

Net Loss %Chg

Net Loss Common Size

Net Loss Attributable to Noncontrolling Interests

Net Loss Attributable to Noncontrolling Interests %Chg

Net Loss Attributable to Noncontrolling Interests Common Size

Net Loss Attributable to Roivant Sciences Ltd.

Net Loss Attributable to Roivant Sciences Ltd. %Chg

Net Loss Attributable to Roivant Sciences Ltd. Common Size

Net Loss per Common Share-Basic and Diluted

Net Loss per Common Share-Basic and Diluted %Chg

Net Loss per Common Share-Basic and Diluted Common Size

Weighted Average Shares Outstanding-Basic and Diluted

Weighted Average Shares Outstanding-Basic and Diluted %Chg

Weighted Average Shares Outstanding-Basic and Diluted Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Diluted %Chg

Diluted Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Mar '23	Mar '22
Total Revenues	61.3	55.3
Total Revenues %Chg	10.8%	—
Revenue, Net
Cost of Sales	13.1	9
Cost of Revenues
Gross Profit	48.2	46.3
Gross Profit Margin	78.6%	83.8%
Selling, General & Administrative Expenses	600.5	775
General and Administrative
Research & Development Expenses	623	622.9
Research and Development
Acquired in-Process Research and Development
Operating Profit	-1,175.3	-1,351.6
Operating Margin	-1,917.9%	-2,444.8%
Interest and Investment Income	-8.6	-1.5
Interest Income
Interest Expense	4.7	0.4
Interest Expense
Non-Operating Income	-105.8	-421.3
Change in Fair Value of Investments
Gain on Sale of Investment
Change in Fair Value of Debt and Liability Instruments
Gain on Termination of Sumitomo Options
Gain on Deconsolidation of Subsidiaries
Other Income, Net
Other Expense, Net
Total Non-Operating Income	-109.6	-422.4
Income Before Provision for Income Taxes	-1,224.8	-923.7
Loss from Continuing Operations Before Income Taxes
Loss Before Income Taxes
Provision for Income Taxes	5.2	0.4
Income Tax Expense
Consolidated Net Income	-1,290.9	-1,215.4
Loss from Continuing Operations, Net of Tax
Net Loss
Net Income Attributable to Minority Interests and Other	-106.4	-78.9
Net Loss Attributable to Noncontrolling Interests
Net Income Attributable to Discontinued Operations	114.6	—
Loss from Discontinued Operations, Net of Tax
Net Income Attributable to Common Shareholders	-1,009	-845.3
Net Loss Attributable to Roivant Sciences Ltd.
Basic EPS	-1.4	-1.3
Diluted EPS	-1.4	-1.3
Basic Weighted Average Shares Outstanding	712.8	669.8
Total Shares Outstanding	760.1	695
Diluted Weighted Average Shares Outstanding	712.8	669.8
EBITDA	-1,156.5	-1,345.7
Effective Tax Rate	-0.4%	-0%